Tag: B.S.2

Poster-Disease-modifying Therapy

Does Frequency and Severity of COVID-19 Differ By Disease Modifying Therapy in MS Patients?

Background: Some authors have reported positive associations between B-cell-depleting (anti-CD20) therapies and COVID-19 infection risk or...

Read More

Poster-Disease-modifying Therapy

Is There ‘Wearing Off’ with Ocrelizumab? Preliminary Results of Symptom Burden on Ocrelizumab, a Longitudinal Study (SymBOLS).

Background: Ocrelizumab (OCR), a humanized, anti-CD20 antibody therapy approved for multiple sclerosis (MS), is given at 6-month intervals....

Read More